Sept. 4 (UPI) -- Health officials on Thursday said they are optimistic about a relatively new HIV antiviral medication called lenacapavir that they hope will reach 2 million people by 2028.
Members of the medical community are calling the drug a "breakthrough" and a "gamechanger." According to State Department officials making the announcement, developers intend to target countries with high HIV/AIDS rates and will focus on slowing or eliminating mother-to-child transmissions.
Lenacapavir, the initial development of which was funded by the National Institutes of Health, is injected twice a year, and has kept 99% of users HIV free in clinical trials, the State Department officials said.
The drug has been approved for use in the United States since 2022.
Related
